text from Zofran birth defect lawsuit

Three New Zofran Birth Defect Lawsuits Filed

The number of Zofran birth defect lawsuits continues to grow. Since May 21, 2015, three new complaints have been added to a litigation that now includes at least 10 individual claims against GlaxoSmithKline. And as more families learn of Zofran’s recent association to increased birth defect risks, the attorneys of ZofranLegal.com expect more complaints to follow.

In New Complaints, Families Say Zofran Caused Congenital Heart Defects, Cleft Lip

text from Zofran birth defect lawsuitFiled in Louisiana, Ohio and Arkansas, the most recent Zofran lawsuits claim that GlaxoSmithKline unlawfully promoted its anti-nausea drug for use as a morning sickness treatment, while concealing evidence of its link to birth defects from physicians and patients across the country.

These parents allege that the company, the world’s 6th largest pharmaceutical manufacturer as of 2014, has failed in its duty to warn the medical community and public of a serious health risk. If they had known of Zofran’s association with an increased risk of major birth defects, plaintiffs claim that they would have never chosen to take the drug during pregnancy.


Family From Arkansas Claims Prenatal Exposure To Zofran Caused Cleft Lip

  • Filed on May 21, 2015
  • In the US District Court for the Eastern District of Arkansas, Western Division
  • Under case number 4:15-cv-00284-BRW
  • Read the complaint

In complaint 4:15-cv-00284-BRW, a couple living outside Little Rock says that their son was born with a partial, or incomplete, cleft lip as a result of the Zofran that his mother was prescribed during the first trimester. The family says that their child underwent a surgical procedure three months after his birth, and that this repair left him with a “permanent scar […] that is often red and inflamed.”

Plaintiffs write that their son has also “experienced developmental delays,” as a result of the sedatives used during his operation. The parents say that they have “cared for and provided support” to their son as he “learn[ed] to walk and talk more slowly than the average infant.” He has seen a “speech therapist, a developmental therapist, and a physical therapist,” plaintiffs claim, in line with the “team” approach that has become the standard of care for children learning to live with the effects of an orofacial cleft.


This recent case is at least the second to be filed by parents on behalf of a child born with an orofacial cleft. In the first, brought against GlaxoSmithKline in the US District Court for the District of Montana, Billings Division, parents claimed that prenatal exposure to Zofran caused their daughter to develop both a cleft lip and cleft palate in utero.

Cleft palate, a split or opening in the roof of the mouth, was linked to Zofran in a 2012 study performed by researchers at Harvard University and Boston University. Reviewing the birth outcomes of more than 10,000 pregnancies, the inter-collegiate team found that women who had been prescribed Zofran during the first trimester were more than twice as likely to deliver children with a cleft palate.


Mothers In Louisiana Say Zofran Led To Critical Congenital Heart Defects

  • Filed on June 8, 2015
  • In the US District Court for the Western District of Louisiana
  • Under case number 6:15-cv-01815-RFD-PJH
  • Read the complaint

In their joined complaint, two mothers from Louisiana claim that exposure to Zofran during early pregnancy caused their unborn daughters to develop congenital heart defects.

The first plaintiff writes that she was prescribed Zofran during January of 2010 to alleviate the symptoms of morning sickness. Her daughter, named as L.D. in court documents, was born July 15, 2010 and quickly diagnosed with three congenital heart defects: ventricular septal defect, atrial septal defect and intermittent tachypnea. Plaintiff claims that her child’s ventricular septal defect, a hole in the barrier that normally separates the heart’s two lower chambers, was surgically repaired. In the complaint, she notes that intermittent tachypnea, a form of rapid breathing in newborns, is a common sign of congestive heart failure.

The second plaintiff’s child, who she claims was exposed to Zofran during early fetal development, was born on August 9, 2005. Soon after delivery, her daughter was diagnosed with accelerated ventricular arrhythmia (AVA), plaintiff writes. AVA is caused by a fault in the heart’s electrical system. The organ’s upper and lower chambers enter periods of arrhythmic contraction; they pump out of sync. AVA can be extremely serious, and plaintiff claims that the defect “nearly caused [her daughter] to die shortly after birth.” The mother says that her child “required intense and regular medical monitoring and testing for the first five years of her life.”


This is at least the seventh Zofran lawsuit filed in relation to congenital heart defects. Plaintiffs cite a series of major epidemiological studies, conducted by researchers in Denmark and Sweden, that have found elevated rates of cardiac septal defects in children exposed to Zofran in utero. Cardiac septal defects, like atrial and ventricular septal defects, involve holes in cardiac tissue that inhibit proper blood flow.

You can find more information on these studies here.


Ohio Parents Allege Daughter’s Fatal Heart Defect Caused By Zofran

  • Filed on June 10, 2015
  • In the US District Court for the Northern District of Ohio, Western Division
  • Under case number 3:15-cv-1166
  • Read the complaint

In the most recent Zofran birth defect lawsuit, a couple from Toledo claims that the anti-nausea drug caused a heart defect that ultimately proved fatal for their late daughter.

Plaintiff writes that she was prescribed Zofran early in a pregnancy that was “otherwise unremarkable” until, nine days before her due date, her unborn child’s “heart rate began to decelerate,” or slow abnormally. Their daughter was born on March 17, 2006, plaintiffs say, and soon diagnosed with a “right ventrical heart defect.” The child was confined to the Intensive Care Unit (ICU) for monitoring. Three days after her birth, their daughter “crashed,” went into cardiac arrest, “and physicians could not revive her,” plaintiffs claim. She died on March 20, 2006.

Plaintiffs write that they have “devoted their time and money to bringing awareness and understanding to heart defects” since their daughter’s untimely passing.


Can Other Families File Zofran Birth Defect Lawsuits?

Any parent who was prescribed Zofran as an “off label” morning sickness treatment and delivered a child with major birth defects may be eligible to bring a claim against GlaxoSmithKline.

ZofranLegal.com is sponsored by an alliance of attorneys dedicated to advocating for the rights of parents and birth defect survivors who believe that prenatal exposure to Zofran may have caused them harm. Our attorneys are now offering free consultations and case eligibility evaluations. To learn more about the ongoing Zofran litigation and your own legal situation, call 1-877-620-8411 or complete our online contact form.